NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $23.12 -0.23 (-0.99%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$23.18 +0.05 (+0.24%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pharvaris Stock (NASDAQ:PHVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharvaris alerts:Sign Up Key Stats Today's Range$22.86▼$23.7750-Day Range$16.56▼$25.1252-Week Range$11.51▼$26.33Volume53,502 shsAverage Volume142,735 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$35.60Consensus RatingModerate Buy Company Overview Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. Read More Pharvaris Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScorePHVS MarketRank™: Pharvaris scored higher than 53% of companies evaluated by MarketBeat, and ranked 512th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePharvaris has only been the subject of 4 research reports in the past 90 days.Read more about Pharvaris' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.71) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 5.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.98% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Pharvaris has recently decreased by 45.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.98% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Pharvaris has recently decreased by 45.59%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.94 News SentimentPharvaris has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Pharvaris this week, compared to 3 articles on an average week.Search Interest2 people have searched for PHVS on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharvaris' insider trading history. Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Stock News HeadlinesPharvaris (NASDAQ:PHVS) Upgraded at Zacks ResearchAugust 21 at 2:00 AM | americanbankingnews.comPharvaris Advances Clinical Pipeline with Strong FinancialsAugust 20, 2025 | msn.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. | InvestorPlace (Ad)Q3 Earnings Estimate for Pharvaris Issued By Leerink PartnrsAugust 19, 2025 | americanbankingnews.comCantor Fitzgerald Lifts Earnings Estimates for PharvarisAugust 17, 2025 | americanbankingnews.comWedbush Issues Positive Estimate for Pharvaris EarningsAugust 17, 2025 | americanbankingnews.comJMP Securities Cuts Pharvaris (NASDAQ:PHVS) Price Target to $52.00August 16, 2025 | americanbankingnews.comPharvaris price target lowered to $52 from $55 at Citizens JMPAugust 13, 2025 | msn.comSee More Headlines PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $19.17 on January 1st, 2025. Since then, PHVS shares have increased by 20.6% and is now trading at $23.12. How were Pharvaris' earnings last quarter? Pharvaris N.V. (NASDAQ:PHVS) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.07. When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an IPO on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. Who are Pharvaris' major shareholders? Top institutional investors of Pharvaris include VR Adviser LLC (3.92%), Soleus Capital Management L.P. (1.40%), Octagon Capital Advisors LP (1.29%) and Sofinnova Investments Inc. (1.12%). How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharvaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Last Earnings8/12/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHVS CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Pharvaris$35.60 High Price Target$52.00 Low Price Target$25.00 Potential Upside/Downside+54.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$145.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.09% Return on Assets-63.34% Debt Debt-to-Equity RatioN/A Current Ratio8.33 Quick Ratio8.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.00 per share Price / Book5.78Miscellaneous Outstanding Shares52,290,000Free Float46,099,000Market Cap$1.21 billion OptionableNot Optionable Beta-2.81 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PHVS) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.